# Darusentan Effect on PET Uptake Heterogeneity

> **NCT00738049** · PHASE2 · COMPLETED · sponsor: **K.Lance Gould** · enrollment: 40 (actual)

## Conditions studied

- Coronary Artery Disease
- Endothelial Dysfunction

## Interventions

- **DRUG:** darusentan 100 mg

## Key facts

- **NCT ID:** NCT00738049
- **Lead sponsor:** K.Lance Gould
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00738049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00738049, "Darusentan Effect on PET Uptake Heterogeneity". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00738049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*